PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for use with other medicines to treat chronic rhinosinusitis ...
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines CSU is an inflammatory skin condition driven in part by type 2 inflammation, which causes sudden ...
Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. indication for uncontrolled chronic obstructive pulmonary disease ...
Paris and Tarrytown, N.Y. March 7, 2023. The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results